Sufugolix: Difference between revisions

Sufugolix
Clinical data
Other names	TAK-013
Routes of; administration	By mouth
Drug class	GnRH modulator; GnRH antagonist; Antigonadotropin
ATC code	None;
Identifiers
	IUPAC name 1-[4-[5-[[benzyl(methyl)amino]methyl]-1-[(2,6-difluorophenyl)methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea;
CAS Number	308831-61-0;
PubChem CID	3038517;
ChemSpider	2302081;
UNII	56S17Z6X9M;
CompTox Dashboard (EPA)	DTXSID40184893 ;
Chemical and physical data
Formula	C36H31F2N5O4S
Molar mass	667.724 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CC1=CC=CC=C1)CC2=C(SC3=C2C(=O)N(C(=O)N3CC4=C(C=CC=C4F)F)C5=CC=CC=C5)C6=CC=C(C=C6)NC(=O)NOC;
	InChI InChI=1S/C36H31F2N5O4S/c1-41(20-23-10-5-3-6-11-23)21-28-31-33(44)43(26-12-7-4-8-13-26)36(46)42(22-27-29(37)14-9-15-30(27)38)34(31)48-32(28)24-16-18-25(19-17-24)39-35(45)40-47-2/h3-19H,20-22H2,1-2H3,(H2,39,40,45); Key:UCQSBGOFELXYIN-UHFFFAOYSA-N;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 12:20, 17 December 2017

Sufugolix (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) (developmental code name TAK-013) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC₅₀Tooltip Half-maximal inhibitory concentration = 0.1 and 0.06 nM for affinity and in vitro inhibition, respectively).^[1] It was under development by Takeda for the treatment of endometriosis and uterine leiomyoma and reached phase II clinical trials for both of these indications, but was subsequently discontinued.^[2]^[3] It seems to have been supplanted by relugolix (TAK-385), which is also under development by Takeda for the treatment of these conditions and has a more favorable drug profile (including reduced cytochrome P450 inhibition and improved in vivo GnRHR antagonistic activity) in comparison.^[4]

Oral administration of sufugolix at a dose of 30 mg/kg to castrated male cynomolgus monkeys resulted in nearly complete suppression of luteinizing hormone levels.^[1] The duration of action was more than 24 hours, indicating a long elimination half-life of the drug.^[1] The suppressive effects of sufugolix on gonadotropin and sex hormone levels are rapidly reversible with discontinuation.^[5]

Unlike various other GnRHR antagonists, sufugolix has been elucidated to be a non-competitive or insurmountable/trapping antagonist of the GnRHR rather than a competitive antagonist.^[6]^[7]

References

^ ^a ^b ^c Sasaki S, Cho N, Nara Y, Harada M, Endo S, Suzuki N, Furuya S, Fujino M (2003). "Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor". J. Med. Chem. 46 (1): 113–24. doi:10.1021/jm020180i. PMID 12502365.
^ Lanier, Marion C.; Feher, Miklos; Ashweek, Neil J.; Loweth, Colin J.; Rueter, Jaimie K.; Slee, Deborah H.; Williams, John P.; Zhu, Yun-Fei; Sullivan, Susan K.; Brown, Michael S. (2007). "Selection, synthesis, and structure–activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists". Bioorganic & Medicinal Chemistry. 15 (16): 5590–5603. doi:10.1016/j.bmc.2007.05.029. ISSN 0968-0896. PMID 17561404.
^ http://adisinsight.springer.com/drugs/800017215
^ Miwa K, Hitaka T, Imada T, Sasaki S, Yoshimatsu M, Kusaka M, Tanaka A, Nakata D, Furuya S, Endo S, Hamamura K, Kitazaki T (2011). "Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor". J. Med. Chem. 54 (14): 4998–5012. doi:10.1021/jm200216q. PMID 21657270.
^ Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N, Furuya S, Fujino M (2003). "Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys". J. Clin. Endocrinol. Metab. 88 (4): 1697–704. doi:10.1210/jc.2002-021065. PMID 12679460.
^ Kohout TA, Xie Q, Reijmers S, Finn KJ, Guo Z, Zhu YF, Struthers RS (2007). "Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism". Mol. Pharmacol. 72 (2): 238–47. doi:10.1124/mol.107.035535. PMID 17409285.
^ Szkudlinski MW (2007). "Challenges and opportunities of trapping ligands". Mol. Pharmacol. 72 (2): 231–4. doi:10.1124/mol.107.038208. PMID 17522183.

External links

Sufugolix - AdisInsight

Template:Signaling peptide/protein receptor modulators

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

[pmid12502365-1] Sasaki S, Cho N, Nara Y, Harada M, Endo S, Suzuki N, Furuya S, Fujino M (2003). "Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor". J. Med. Chem. 46 (1): 113–24. doi:10.1021/jm020180i. PMID 12502365.

[LanierFeher2007-2] Lanier, Marion C.; Feher, Miklos; Ashweek, Neil J.; Loweth, Colin J.; Rueter, Jaimie K.; Slee, Deborah H.; Williams, John P.; Zhu, Yun-Fei; Sullivan, Susan K.; Brown, Michael S. (2007). "Selection, synthesis, and structure–activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists". Bioorganic & Medicinal Chemistry. 15 (16): 5590–5603. doi:10.1016/j.bmc.2007.05.029. ISSN 0968-0896. PMID 17561404.

[AdisInsight-3] ttp://adisinsight.springer.com/drugs/800017215

[pmid21657270-4] Miwa K, Hitaka T, Imada T, Sasaki S, Yoshimatsu M, Kusaka M, Tanaka A, Nakata D, Furuya S, Endo S, Hamamura K, Kitazaki T (2011). "Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor". J. Med. Chem. 54 (14): 4998–5012. doi:10.1021/jm200216q. PMID 21657270.

[pmid12679460-5] Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N, Furuya S, Fujino M (2003). "Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys". J. Clin. Endocrinol. Metab. 88 (4): 1697–704. doi:10.1210/jc.2002-021065. PMID 12679460.

[pmid17409285-6] Kohout TA, Xie Q, Reijmers S, Finn KJ, Guo Z, Zhu YF, Struthers RS (2007). "Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism". Mol. Pharmacol. 72 (2): 238–47. doi:10.1124/mol.107.035535. PMID 17409285.

[pmid17522183-7] Szkudlinski MW (2007). "Challenges and opportunities of trapping ligands". Mol. Pharmacol. 72 (2): 231–4. doi:10.1124/mol.107.038208. PMID 17522183.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

@@ Line 53: / Line 53: @@
 Oral administration of sufugolix at a dose of 30&nbsp;mg/kg to [[castration|castrated]] male [[cynomolgus monkey]]s resulted in nearly complete suppression of [[luteinizing hormone]] levels.<ref name="pmid12502365" /> The [[duration of action]] was more than 24 hours, indicating a long [[elimination half-life]] of the drug.<ref name="pmid12502365" /> The suppressive effects of sufugolix on [[gonadotropin]] and [[sex hormone]] levels are rapidly reversible with discontinuation.<ref name="pmid12679460">{{cite journal | vauthors = Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N, Furuya S, Fujino M | title = Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys | journal = J. Clin. Endocrinol. Metab. | volume = 88 | issue = 4 | pages = 1697–704 | year = 2003 | pmid = 12679460 | doi = 10.1210/jc.2002-021065 | url = }}</ref>
-Unlike various other GnRHR antagonists, sufugolix has been elucidated to be a [[non-competitive antagonist|non-competitive or insurmountable/trapping antagonist]] of the GnRHR.<ref name="pmid17409285">{{cite journal | vauthors = Kohout TA, Xie Q, Reijmers S, Finn KJ, Guo Z, Zhu YF, Struthers RS | title = Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism | journal = Mol. Pharmacol. | volume = 72 | issue = 2 | pages = 238–47 | year = 2007 | pmid = 17409285 | doi = 10.1124/mol.107.035535 | url = }}</ref><ref name="pmid17522183">{{cite journal | vauthors = Szkudlinski MW | title = Challenges and opportunities of trapping ligands | journal = Mol. Pharmacol. | volume = 72 | issue = 2 | pages = 231–4 | year = 2007 | pmid = 17522183 | doi = 10.1124/mol.107.038208 | url = }}</ref>
+Unlike various other GnRHR antagonists, sufugolix has been elucidated to be a [[non-competitive antagonist|non-competitive or insurmountable/trapping antagonist]] of the GnRHR rather than a [[competitive antagonist]].<ref name="pmid17409285">{{cite journal | vauthors = Kohout TA, Xie Q, Reijmers S, Finn KJ, Guo Z, Zhu YF, Struthers RS | title = Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism | journal = Mol. Pharmacol. | volume = 72 | issue = 2 | pages = 238–47 | year = 2007 | pmid = 17409285 | doi = 10.1124/mol.107.035535 | url = }}</ref><ref name="pmid17522183">{{cite journal | vauthors = Szkudlinski MW | title = Challenges and opportunities of trapping ligands | journal = Mol. Pharmacol. | volume = 72 | issue = 2 | pages = 231–4 | year = 2007 | pmid = 17522183 | doi = 10.1124/mol.107.038208 | url = }}</ref>
 ==See also==